InvestorsHub Logo
Followers 20
Posts 1059
Boards Moderated 0
Alias Born 04/01/2013

Re: Bio_pete post# 229123

Thursday, 11/21/2019 9:20:28 AM

Thursday, November 21, 2019 9:20:28 AM

Post# of 425811
DCF is overrated in this scenario because the peak sales numbers have such a wide range. Also interest rates are extremely low so it factors in way less, we are not BP doing an incredibly detailed analysis to get an exact range to calculate a share price to offer, we are individual investors generalizing a reasonable BO price based on some high end numbers.
If these stocks sell for 3-5 times peak sales then the peak sales number is more important, # of other bidders is more important.

The last BO I was involved in they started at 70 million offer countered with 100 million and ended up at 93 million and had no competitive bidders. Company worth 150 million now. I saw the calculations and DCF is over-rated and not of much use for what we are doing on this board to estimate a price.

It's not hard, 40 billion in sales by 2030, is 30 billion in cash flow, so 20 billion seems right considering if your BP the potential is there for 80 billion in sales and half a billion a year forever as OTC. Odds are really high you recoup your investment, especially if some is paid in stock, and you have potential to really come out ahead. What's REALLY the only number that matters? How much revenue is reasonable by 2030. And that can range by 10-20 billion dollars which more than offsets any DCF adjustment.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News